On-demand Webcast

Share

Program Content

Activities

  • HER2- and TROP-2–Targeted Tx in Breast Cancer
    Optimizing Integration of Precision Therapy Into the Treatment of HER2-Low, HR-Positive, and Triple Negative Breast Cancer: A Focus on HER2 Targeted and TROP-2–Targeted Therapy
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 20, 2023

    Expires: June 19, 2024

Faculty

cover img faculity

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine, Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research), Division of Medical Oncology
Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

cover img faculity

Sara A. Hurvitz, MD, FACP

Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

cover img faculity

Shanu Modi, MD

Professor of Medicine
Section Head, HER2 Breast Program
Breast Medicine Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Provided by

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

AstraZeneca

Daiichi Sankyo

Gilead Sciences, Inc.